These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

798 related articles for article (PubMed ID: 17984166)

  • 1. Rosuvastatin in older patients with systolic heart failure.
    Kjekshus J; Apetrei E; Barrios V; Böhm M; Cleland JG; Cornel JH; Dunselman P; Fonseca C; Goudev A; Grande P; Gullestad L; Hjalmarson A; Hradec J; Jánosi A; Kamenský G; Komajda M; Korewicki J; Kuusi T; Mach F; Mareev V; McMurray JJ; Ranjith N; Schaufelberger M; Vanhaecke J; van Veldhuisen DJ; Waagstein F; Wedel H; Wikstrand J;
    N Engl J Med; 2007 Nov; 357(22):2248-61. PubMed ID: 17984166
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of statin therapy according to plasma high-sensitivity C-reactive protein concentration in the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA): a retrospective analysis.
    McMurray JJ; Kjekshus J; Gullestad L; Dunselman P; Hjalmarson A; Wedel H; Lindberg M; Waagstein F; Grande P; Hradec J; Kamenský G; Korewicki J; Kuusi T; Mach F; Ranjith N; Wikstrand J;
    Circulation; 2009 Dec; 120(22):2188-96. PubMed ID: 19917888
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Plasma concentration of amino-terminal pro-brain natriuretic peptide in chronic heart failure: prediction of cardiovascular events and interaction with the effects of rosuvastatin: a report from CORONA (Controlled Rosuvastatin Multinational Trial in Heart Failure).
    Cleland JG; McMurray JJ; Kjekshus J; Cornel JH; Dunselman P; Fonseca C; Hjalmarson A; Korewicki J; Lindberg M; Ranjith N; van Veldhuisen DJ; Waagstein F; Wedel H; Wikstrand J;
    J Am Coll Cardiol; 2009 Nov; 54(20):1850-9. PubMed ID: 19892235
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Osteoprotegerin predicts progression of chronic heart failure: results from CORONA.
    Ueland T; Dahl CP; Kjekshus J; Hulthe J; Böhm M; Mach F; Goudev A; Lindberg M; Wikstrand J; Aukrust P; Gullestad L
    Circ Heart Fail; 2011 Mar; 4(2):145-52. PubMed ID: 21216833
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Number needed to treat with rosuvastatin to prevent first cardiovascular events and death among men and women with low low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein: justification for the use of statins in prevention: an intervention trial evaluating rosuvastatin (JUPITER).
    Ridker PM; MacFadyen JG; Fonseca FA; Genest J; Gotto AM; Kastelein JJ; Koenig W; Libby P; Lorenzatti AJ; Nordestgaard BG; Shepherd J; Willerson JT; Glynn RJ;
    Circ Cardiovasc Qual Outcomes; 2009 Nov; 2(6):616-23. PubMed ID: 20031900
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [No reason to start treatment with statins in patients with moderate to severe heart failure].
    Stalenhoef AF
    Ned Tijdschr Geneeskd; 2008 Mar; 152(9):486-8. PubMed ID: 18389878
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rosuvastatin: a review of its use in the prevention of cardiovascular disease in apparently healthy women or men with normal LDL-C levels and elevated hsCRP levels.
    Carter NJ
    Am J Cardiovasc Drugs; 2010; 10(6):383-400. PubMed ID: 21090831
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Twelve-week, multicenter, randomized, open-label comparison of the effects of rosuvastatin 10 mg/d and atorvastatin 10 mg/d in high-risk adults: a DISCOVERY study.
    Strandberg TE; Feely J; Sigurdsson EL;
    Clin Ther; 2004 Nov; 26(11):1821-33. PubMed ID: 15639694
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Low-density lipoprotein cholesterol (LDL-C) levels and LDL-C goal attainment among elderly patients treated with rosuvastatin compared with other statins in routine clinical practice.
    Harley CR; Gandhi S; Blasetto J; Heien H; Sasane R; Nelson SP
    Am J Geriatr Pharmacother; 2007 Sep; 5(3):185-94. PubMed ID: 17996658
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [To treat or not to treat with statins patients with chronic heart failure?].
    Hradec J
    Vnitr Lek; 2009 Sep; 55(9):802-7. PubMed ID: 19785380
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety of rosuvastatin: update on 16,876 rosuvastatin-treated patients in a multinational clinical trial program.
    Shepherd J; Vidt DG; Miller E; Harris S; Blasetto J
    Cardiology; 2007; 107(4):433-43. PubMed ID: 17363845
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rosuvastatin and cardiovascular events in patients undergoing hemodialysis.
    Fellström BC; Jardine AG; Schmieder RE; Holdaas H; Bannister K; Beutler J; Chae DW; Chevaile A; Cobbe SM; Grönhagen-Riska C; De Lima JJ; Lins R; Mayer G; McMahon AW; Parving HH; Remuzzi G; Samuelsson O; Sonkodi S; Sci D; Süleymanlar G; Tsakiris D; Tesar V; Todorov V; Wiecek A; Wüthrich RP; Gottlow M; Johnsson E; Zannad F;
    N Engl J Med; 2009 Apr; 360(14):1395-407. PubMed ID: 19332456
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Double-blind, randomized, placebo-controlled study of high-dose HMG CoA reductase inhibitor therapy on ventricular remodeling, pro-inflammatory cytokines and neurohormonal parameters in patients with chronic systolic heart failure.
    Krum H; Ashton E; Reid C; Kalff V; Rogers J; Amarena J; Singh B; Tonkin A
    J Card Fail; 2007 Feb; 13(1):1-7. PubMed ID: 17338996
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Galectin-3 predicts response to statin therapy in the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA).
    Gullestad L; Ueland T; Kjekshus J; Nymo SH; Hulthe J; Muntendam P; Adourian A; Böhm M; van Veldhuisen DJ; Komajda M; Cleland JG; Wikstrand J; McMurray JJ; Aukrust P;
    Eur Heart J; 2012 Sep; 33(18):2290-6. PubMed ID: 22513778
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Statin therapy for systolic heart failure. The CORONA trial (Controlled Rosuvastatin Multinational Trial in Heart Failure)].
    Angermann CE; Nitschmann S
    Internist (Berl); 2008 Jul; 49(7):884-6. PubMed ID: 18427760
    [No Abstract]   [Full Text] [Related]  

  • 16. Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial.
    Tavazzi L; Maggioni AP; Marchioli R; Barlera S; Franzosi MG; Latini R; Lucci D; Nicolosi GL; Porcu M; Tognoni G;
    Lancet; 2008 Oct; 372(9645):1231-9. PubMed ID: 18757089
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The safety of rosuvastatin in comparison with other statins in over 25,000 statin users in the Saskatchewan Health Databases.
    García-Rodríguez LA; González-Pérez A; Stang MR; Wallander MA; Johansson S
    Pharmacoepidemiol Drug Saf; 2008 Oct; 17(10):953-61. PubMed ID: 18425987
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of rosuvastatin and atorvastatin in patients with hypercholesterolemia and a high risk of coronary heart disease: a randomized, controlled trial.
    Schwartz GG; Bolognese MA; Tremblay BP; Caplan R; Hutchinson H; Raza A; Cressman M
    Am Heart J; 2004 Jul; 148(1):e4. PubMed ID: 15215813
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Soluble glycoprotein 130 predicts fatal outcomes in chronic heart failure: analysis from the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA).
    Askevold ET; Nymo S; Ueland T; Gravning J; Wergeland R; Kjekshus J; Yndestad A; Cleland JG; McMurray JJ; Aukrust P; Gullestad L
    Circ Heart Fail; 2013 Jan; 6(1):91-8. PubMed ID: 23230311
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Jupiter study, CRP screening, and aggressive statin therapy-implications for the primary prevention of cardiovascular disease.
    Kones R
    Ther Adv Cardiovasc Dis; 2009 Aug; 3(4):309-15. PubMed ID: 19460829
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 40.